Growth hormone response to apomorphine in panic disorder: Comparison with major depression and normal controls
Tóm tắt
Several lines of evidence suggest that dopamine might be involved in anxiety states. In the present study we assessed the growth hormone (GH) response to 0.5 mg apomorphine (a dopaminergic agonist) in 10 male drug-free inpatients meeting Research Diagnostic Criteria for panic disorder who were compared with 10 male major depressive inpatients and 10 male normal controls. The three groups differed significantly in the GH peak response (mean ± SD): 27.8±12.5 ng/ml in panics, 5.4±4.0 ng/ml in major depressives, and 25.8±11.3 ng/ml in normal controls (F(2,27)=15.3;P=0.00003). Although there were significant differences between panics and major depressives (P=0.00004), and between major depressives and controls (P=0.00004), panics did not significantly differ from controls. These results do not support the hypothesis of an overlap between panic and affective disorders, and suggest that the hypothalamo-GH-somatomedin axis could be intact in panic disorder.
Tài liệu tham khảo
Akiskal HS, Lemmi H, Dickson H, King D, Yerevanian B, Van Valkenburg C (1984) Chronic depressions. Part 2. Sleep EEG differentiation of primary dysthymic disorders from anxious depressions. J Affect Disord 6:287–295
Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR (1990) Noradrenergic dysregulation in panic disorder. In Ballenger JC (ed) Neurobiology of panic disorder. Alan R. Liss, New York, pp 91–105
Gurguis GNM, Mefford IN, Uhde TW (1991) Hypothalamic-pituitary-adrenocortical activity in panic disorder: relationship to plasma catecholamine metabolites. Biol Psychiatry 30:502–506
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Nutt DJ, Glue P, Lawson C (1990) The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry 14: 737–752
Pecknold JC, Luthe L (1990) Sleep studies and neurochemical correlates in panic disorder and agoraphobia. Prog Neuropsychopharmacol Biol Psychiatry 14:753–758
Pitchot W, Ansseau M, Gonzalez Moreno A, Hansenne M, von Frenckell R (1992) Dopaminergic function in panic disorder: comparison with major and minor depression. Biol Psychiatry 32:1004–1011
Pitchot W, Gonzalez Moreno A, Hansenne M, Ansseau M (1995) Effect of antidepressant therapy on the growth hormone response to apomorphine. Neuropsychobiology (in press)
Roy-Byrne PP, Uhde TW, Gold PW, Rubinow DR, Post RM (1985a) Neuroendocrine abnormalities in panic disorder. Psychopharmacol Bull 3:550–554
Roy-Byrne PP, Bierer LM, Uhde TW (1985b) The dexamethasone suppression test in panic disorder: comparison with normal controls. Biol Psychiatry 20:1237–1240
Roy-Byrne PP, Uhde TW, Sack DA, Linnoila M, Post RM (1986) Plasma HVA and anxiety in patients with panic disorder. Biol Psychiatry 21:847–849
Schittecatte M, Charles G, Machowski R, Wilmotte J (1989) Tricyclic wash-out and growth hormone response to clonidine. Br J Psychiatry 154:858–863
Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990) Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 147: 217–220
Stein MB, Uhde TW (1991) Endocrine, cardiovascular, and behavioral effects of intravenous protirelin in patients with panic disorder. Arch Gen Psychiatry 48:148–155
Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger JP, Vittone B, Gurguis G, Geraci M, Black B, Post RM (1992) Evidence for hypothalamo-growth hormone dysfunction in panic disorder; profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 6:101–118